Cantor Fitzgerald Maintains Buy Rating on Novavax
Analyst Pete Stavropoulos at Cantor Fitzgerald has reaffirmed a 'Buy' rating and a $18 price target for Novavax, Inc.
Stocks · News reference
What's Going On With Novavax Stock?
Shares of Novavax are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine authorizations against the company's broader strategic pivot toward licensing and cost-structure optimization.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports
Moderna's stock fell 18% after reports of a data leak regarding its personalized melanoma vaccine showed a 42% reduction in recurrence or death risk when paired with Merck's Keytruda—lower than Phase II results of 49%. The full Phase 3 results were scheduled for release on October 24, and the leaked figures fell short of market expectations despite the company's 600% gain in 2026.
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
Shah Capital Cuts Novavax Stake To 6.39%, Sells 2.87M Shares At Average Price Of $11.35/Share, Restructures Holdings Into Family Office
- SEC Filing
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.
'HHS launches project to speed up clinical trials' - Axios